Table 5.

Results of selected phase III trials with copunds that showed activity in phase II trials

Compounds active in Phase II trial	Pivotal phase III trial in STS population	Results of Phase III trial	Marketing authorization in STS
Regorafenib	No	NA	No
Trabectedin	NCT01343277	Improvement in PFS, no improvement in OS	Yes
Aldoxorubicin	NCT02049905	No improvement of OS	No
Eribulin	NCT01327885	Improvement in OS	Yes
Gemcitabine + sirolimus	No	NA	No
Palbociclib	No	NA	No
Pazopanib	NCT00753688	Improvement in PFS, no improvement in OS	Yes
Olaratumab	NCT02451943	No improvement in OS	No

NA not applicable, OS overall survival, PFS progression-free survival